PCIB News - Candlesense

PCI Biotech half-year interim 2025 report

(PCIB) Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation.

Earnings

2 days ago

Read more globenewswire

PCI Biotech: Invitation to first half 2025 results presentation and corporate update

Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time).

Earnings

5 days ago

Read more globenewswire

Flaggemelding

Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,...

Could the 5.36% ownership trigger further buying activity or influence corporate actions that might impact the stock's liquidity and price? Is this acquisition part of a broader strategic move by Øystein Barmen that could affect PCI Biotech's operations or partnerships? What does Hawkeye Invest AS' increased stake indicate about its confidence in PCI Biotech's future performance?

Ownership

9 days ago

Read more globenewswire

PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations

Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manuf...

How might this development halt influence the company's valuation relative to peers in the viral vector manufacturing space? What alternative R&D projects or partnerships is PCI Biotech pursuing to offset the loss of the PCL program? How will the discontinuation of PCL technology affect PCI Biotech's revenue forecasts and cash flow?

R&d

13 days ago

Read more globenewswire